肝機能改善薬ＴＡ‐５１０の体内動態　（第三報）　　ヒト肝臓におけるＴＡ‐５１０還元酵素の同定

DOI Web Site 参考文献22件

書誌事項

タイトル別名
  • Studies on the Metabolic Fate of TA-510, a Hepatic Anti-inflammatory Agent. (III).Ildentitication of TA-510 Reductase in Human Liver.
  • : Identification of TA-510 Reductase in Human Liver
  • : ヒト肝臓におけるTA-510還元酵素の同定

この論文をさがす

抄録

To identify TA-510 reductase and obtain information on the stereochemical aspects, the reductase activity has been studied in subcellular fractions from 15 human livers, and finally purified using TA-510 enantiomers as substrates.<BR> 1. This activity was present in the cytosolic fraction and exhibited strong product stereoselectivity, i.e. both enantiomers were reduced exclusively to trans-alcohol (M1), but not cis-alcohol. Human liver microsomes showed practically no ketone reductase activity.<BR> 2. There was also a remarkable variation between the subjects in the substrate stereoselectivity, suggesting that racemic TA-510 was metabolized by at least two reductive enzymes with different stereochemical requirements.<BR> 3. The enzyme responsible for the reduction of (+)-TA-510 enantiomer was co-eluted with carbonyl reductase during purification steps, and separated from another enzyme with preference to (-)-TA-510 enantiomer as a substrate. Identity of (+) -TA-510 reductase and carbonyl reductase was also suggested by comparing the kinetic analysis and susceptibility to inhibitors of human liver cytosols and the purified enzyme.<BR> 4. (-)-TA-510 reductase was purified to a homogeneous protein and was shown as a monomeric protein with a molecular weight of 36 kDa. Amino acid sequences of five peptides obtained by proteolytic digestion of the purified enzyme were completely identical to the corresponding regions of previously reported 3α-hydroxysteroid/dihydrodiol dehydrogenase.

収録刊行物

  • 薬物動態

    薬物動態 15 (4), 338-348, 2000

    日本薬物動態学会

参考文献 (22)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ